eMed™ and Quest Diagnostics Collaborate to Offer Guided COVID-19 Rapid Antigen Testing to Help Employers Foster Safer Workplaces
Testing can be performed by individuals from the comfort of their home, at their convenience, to encourage compliance and limit exposure in an office setting
New testing option complements Quest's current return-to-work solutions featuring molecular diagnostic and antibody testing
MIAMI and SECAUCUS, NJ — August 11, 2021 — eMed™, a telehealth company democratizing healthcare through digital-point-of-care solutions, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, are collaborating to bring clinician-guided rapid antigen testing for COVID-19 to employers seeking to foster safer environments by decreasing the risk of COVID-19 exposure in their workplaces.
Through the collaboration, the two companies will leverage the BinaxNOW™ COVID-19 Ag Card Home Test, a self-administered, nasal swab antigen test that provides results in 15 minutes. An eMed Certified Guide supervises the testing process virtually, confirming employee identity, overseeing proper sample collection, and authenticating results during a telehealth visit.
Quest Diagnostics is the leading provider of employer population health and workplace drug testing services, serving thousands of employers across the United States. The company's services range from lab and biometric screening to behavioral and mental health interventions to telehealth, virtual care and flu clinics.
Organizations are now able to have rapid test kits delivered straight to employees’ homes. Individuals will receive their validated results via a digital health pass on their smart device, and employers will have access to a portal with consolidated employee test results. Individuals who test positive will have the option to undergo additional molecular testing through Quest Diagnostics to confirm their positive result. Quest provides gold-standard molecular diagnostic testing for COVID-19.
This solution uniquely offers employers the ability to efficiently screen for COVID-19 using rapid antigen testing and confirmatory molecular testing when necessary. Employees on international travel may use the BinaxNOW™ COVID-19 Ag Card Home Test during their trip to meet the CDC testing requirements for reentry into the U.S. Because rapid antigen testing specimen collection can be performed at home, or during business travel, testing may help identify infected individuals before they are able to enter the office, helping to reduce risk for other employees.
“The eMed digital point-of-care platform for verified COVID-19 testing and results reporting is innovative in the health testing and diagnostic services space, and that is our intent,” said Dr. Patrice Harris, eMed Co-Founder and CEO. “We are thrilled to be partnering with an industry leader like Quest Diagnostics to reach more people and further mitigate the impact of COVID-19 with convenient, accessible testing services, especially given the emergence of worrisome variants.”
“Employers are eager to keep their workplaces as safe as possible for their employees and their customers. While testing is one way to do this, many employees are unsure how to implement a testing program that will be effective and easy to execute,” said Jay G. Wohlgemuth, M.D., Senior Vice President and Chief Medical Officer, and head of Quest's Employer Population Health business. “Our collaboration with eMed allows employers to offer guided rapid antigen testing with access to gold-standard molecular testing to confirm positive results, providing an unmatched level of ease and quality, ensuring the likelihood of uptake by employees.”
- This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA;
- This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
eMed (www.eMed.com) is a telehealth company democratizing healthcare with a digital point-of-care platform that provides fast, easy and affordable at-home health care testing, supervised and guided online by eMed Certified Guides. We embrace quantitative medicine to deliver prescribed tests and treatments directly to individuals, driving better and more cost-effective health outcomes.
About Quest Diagnostics Employer Population Health
Quest Diagnostics Employer Population Health is the leader in solutions that help improve outcomes and costs for employers. With nationwide lab access and insights from clinical data, Quest Diagnostics provides health screenings and related population health solutions and utilizes screening insights to help identify chronic disease risks, connect employees to needed in-network care, and empower better health. For more information, visit www.QuestForHealth.com.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
# # #